PANKU-Breast02
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
- NCT06382142 ↗
- Active, not recruiting
- Sichuan Baili Pharmaceutical Co., Ltd.
- Standard
We haven't built an HCP commentary report on PANKU-Breast02 (izalontamab brengitecan (BL-B01D1) in unresectable locally advanced or metastatic triple-negative breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from all 16 indexed sources (Feb 2026 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether results will be confirmed in a global population
- Whether iza-bren has a role in earlier treatment settings
- Whether hematologic toxicity is manageable
Also discussed: EGFR-HER3 targeting beyond TROP2.
Indexed commentary on PANKU-Breast02 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 10 | |
| YouTube | 4 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer After Taxane Failure
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- BL-B01D1; Eribulin; Vinorelbine; Gemcitabine; Capecitabine
- Arms
- BL-B01D1 · Experimental
- Eribulin or Vinorelbine or Gemcitabine or Capecitabine · Experimental
- Enrollment
- 418
- Primary outcomes
- Progression-free survival (PFS)
- Overall survival (OS)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. with Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- Start
- Jun 21, 2024
- Primary completion
- Jan 13, 2026
- Results posted
- No
- Registry record
- NCT06382142 · updated Jul 23, 2026